- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
- Successful national roll-out of flagship product SimpliClear in the Spanish market
- Partnership with Vitaldent, Europe's largest dental chain, positions BioMers to establish leading presence in the European aesthetic orthodontic market
Nanostart-holding BioMers Pte Ltd, a Singapore medical device company, announced today the successful completion of its flagship product's - SimpliClear - nationwide launch in Spain. The Spanish launch of the world's first completely clear braces materialized in partnership with Vitaldent, Europe's largest dental chain and one of the leading chains of clinics globally.
BioMers is now offering SimpliClear in all 380 clinics of Vitaldent throughout the country. The company has signed a five-year partnership agreement with Vitaldent and set up its European headquarters in Madrid, Spain.
Through these latest developments, BioMers is in its own terms positioning itself to play a leading role as a major innovator in the growing aesthetic orthodontic segment in Europe, which represents one-third of the global orthodontic market.
BioMers is a spin-off from the National University of Singapore and portfolio company of New Asia Investments, a Singapore-based venture capital firm. Nanostart AG holds an interest of approximately 30 percent in New Asia Investments.
About Nanostart AG
Nanostart AG is a leading nanotechnology venture capital company. The company invests venture capital (VC) in promising young nanotechnology companies. Nanostart invests globally and at different phases of development. Emphasis of investments is on especially innovative industries such as cleantech, life sciences, and IT/electronics. Nanostart invests either directly in nanotechnology companies or through a regional nanotechnology fund. The headquarters of Nanostart AG is in Frankfurt, Germany.
BioMers Pte. Ltd. is a Singapore-based medical device company that has developed novel polymer composite products for numerous biomedical applications. The company’s flagship product is the SimpliClear® braces system, which is the world’s first and only aesthetic solution for all types of orthodontic treatments. This translucent, almost invisible braces system is customized to each patient, providing faster and better results. Established in 2005, BioMers is a spin-off company from the National University of Singapore, where the technology was invented. BioMers has received seed funding from NUS Enterprise, venture capital funding from the Nanostart Singapore Early Stage Venture Fund, and grants from government agencies, including SPRING Singapore and the Economic Development Board. For more information, visit www.simpliclear.com.
This notice constitutes neither an offer to sell nor a solicitation of offers to purchase or subscribe to securities. There will be no public offering of securities of Nanostart AG in conjunction with the existing listing of its shares in the “Entry Standard” segment of the regulated unofficial market (Freiverkehr) on the Frankfurt Stock Exchange. This notice does not constitute a securities prospectus. Neither this notice nor the information contained within is intended for direct or indirect distribution within Canada, Australia, or Japan.
For more information, please click here
Dr. Hans Joachim Dürr
Head of Corporate Communications
P: +49 69-21 93 96 111
F: +49 69-21 93 96 150
Copyright © Nanostart AGIf you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
News and information
Nanotechnology identifies brain tumor types through MRI 'virtual biopsy' in animal studies: If results are confirmed in humans, tumor cells could someday be diagnosed by MRI imaging and treated with tumor-specific IV injections; new NIH grant will fund future study May 27th, 2015
BESSTECH Announces $250K Investment from Eastern New York Angels : Funding will accelerate commercialization of BESSTECH’s innovative lithium-ion battery electrode technology and enable hiring of key personnel May 13th, 2015
Harris & Harris Group Sponsors NYC American Heart Association's Health Sciences Innovation Investment Forum: Co-founder of Harris & Harris Group Portfolio Company TARA Biosystems to Speak About the Value of Tissue Engineering Technology April 21st, 2015
Long Island Capital Alliance Announces Participants for Brookhaven National Laboratory Technology Transfer Capital Forum on May 8: Keynote Speaker Dr. Doon Gibbs, Director of Brookhaven National Laboratory April 16th, 2015
DiATOME enables surface preparation for AFM and FIB May 19th, 2015
Graphene reduces wear of alumina ceramic March 26th, 2015
'Additive manufacturing' could greatly improve diabetes management March 17th, 2015